Designer drugs 2015: Assessment and management

Addiction Science and Clinical Practice

Volumn 10, Issue 1, 2015, Pages

  Weaver, Michael F ^a   Hopper, John A ^b   Gunderson, Erik W ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b ST JOSEPH MERCY HOSPITAL   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

25I NBOMe; Bath salts; Cathinones; Designer drugs; Hallucinogens; Legal high; Mephedrone; Methylenedioxypyrovalerone; Methylone; N bomb; Spice; Synthetic cannabinoids

Indexed keywords

ALKALOID; CANNABINOID; CATHINONE; DESIGNER DRUG; HYPNOTIC SEDATIVE AGENT; PSYCHEDELIC AGENT; PSYCHOTROPIC AGENT;

COGNITIVE THERAPY; COUNSELING; HUMAN; PATIENT EDUCATION; PHYSIOLOGIC MONITORING; SUBSTANCE ABUSE; SUBSTANCE-RELATED DISORDERS;

ALKALOIDS; CANNABINOIDS; COGNITIVE THERAPY; COUNSELING; DESIGNER DRUGS; HALLUCINOGENS; HUMANS; HYPNOTICS AND SEDATIVES; MONITORING, PHYSIOLOGIC; PATIENT EDUCATION AS TOPIC; PSYCHOTROPIC DRUGS; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS;

EID: 84964698654     PISSN: 19400632     EISSN: 19400640     Source Type: Journal    
DOI: 10.1186/s13722-015-0024-7     Document Type: Review

References (73)

1. King LA, Kicman AT. A brief history of 'new psychoactive substances'. Drug Test Anal. 2011;3:401-3.
2. Johnson LA, Johnson RL, Portier RB. Current "legal highs". J Emerg Med. 2013;44:1108-15.
3. Kelly JP. Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. Drug Test Anal. 2011;3:439-53.
4. Brandt SD, Sumnall HR, Measham F, Cole J. Analyses of second-generation 'legal highs' in the UK: initial findings. Drug Test Anal. 2010;2:377-82.
5. Wiegand TJ, Wax PM, Schwartz T, Finkelstein Y, Gorodetsky R, Brent J. The toxicology investigators consortium case registry - the 2011 experience. J Med Toxicol. 2012;8:360-77.
6. Winstock A, Mitcheson L, Ramsey J, Davies S, Puchnarewicz M, Marsden J. Mephedrone: use, subjective effects and health risks. Addiction. 2011;106:1991-6.
7. Winstock AR, Mitcheson LR, Deluca P, Davey Z, Corazza O, Schifano F. Mephedrone, new kid for the chop? Addiction. 2011;106:154-61.
8. Spiller HA, Ryan ML, Weston RG, Jansen J. Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States. Clin Toxicol (Phila). 2011;49:499-505.
9. Carhart-Harris RL, King LA, Nutt DJ. A web-based survey on mephedrone. Drug Alcohol Depend. 2011;118:19-22.
10. Hu X, Primack BA, Barnett TE, Cook RL. College students and use of K2: an emerging drug of abuse in young persons. Subst Abuse Treat Prev Policy. 2011;6:16.
11. Johnston L, O'Malley P, Miech R, Bachman J, Schulenberg J. Monitoring The Future National Survey Results on Drug Use: 1975-2013: Overview, Key Findings on Adolescent Drug Use. Ann Arbor: University of Michigan Institute for Social Research; 2014.
12. Gunderson EW, Haughey HM, Ait-Daoud N, Joshi AS, Hart CL. A survey of synthetic cannabinoid consumption by current cannabis users. Subst Abus. 2014;35:184-9.
13. Dargan PI, Albert S, Wood DM. Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. QJM. 2010;103:875-9.
14. Camp NE. Synthetic cannabinoids. J Emerg Nurs. 2011;37:292-3.
15. Winstock AR, Barratt MJ. Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend. 2013;131:106-11.
16. SAMHSA Center for Behavioral Health Statistics and Quality. The NSDUH Report: Trends in Adolescent Substance Use and Perception of Risk from Substance Use. Rockville: Substance Abuse and Mental Health Services Administration; 2013.
17. Vardakou I, Pistos C, Spiliopoulou C. Drugs for youth via internet and the example of mephedrone. Toxicol Lett. 2011;201:191-5.
18. Loeffler G, Hurst D, Penn A, Yung K. Spice, bath salts, and the U.S. military: the emergence of synthetic cannabinoid receptor agonists and cathinones in the U.S. armed forces. Mil Med. 2012;177:1041-8.
19. Baumann MH, Ayestas Jr MA, Partilla JS, Sink JR, Shulgin AT, Daley PF, et al. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology. 2012;37:1192-203.
20. Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M. Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products. Neuropsychopharmacology. 2013;38:552-62.
21. Gunderson EW, Kirkpatrick MG, Willing LM, Holstege CP. Substituted cathinone products: a new trend in "bath salts" and other designer stimulant drug use. J Addict Med. 2013;7:153-62.
22. Hill SL, Thomas SH. Clinical toxicology of newer recreational drugs. Clin Toxicol (Phila). 2011;49:705-19.
23. Brunt TM, Poortman A, Niesink RJ, van den Brink W. Instability of the ecstasy market and a new kid on the block: mephedrone. J Psychopharmacol. 2011;25:1543-7.
24. Sammler EM, Foley PL, Lauder GD, Wilson SJ, Goudie AR, O'Riordan JI. A harmless high? Lancet. 2010;376:742.
25. Davies S, Wood DM, Smith G, Button J, Ramsey J, Archer R. Purchasing 'legal highs' on the internet - is there consistency in what you get? QJM. 2010;103:489-93.
26. Weaver MF, Schnoll SH. In Addictions: A Comprehensive Guidebook. In: McCrady BS, Epstein EE, editors. Stimulants: amphetamines and cocaine. New York: Oxford University Press USA; 1999. p. 105-20.
27. Uchiyama N, Kikura-Hanajiri R, Ogata J, Goda Y. Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci Int. 2010;198:31-8.
28. Harris CR, Brown A. Synthetic cannabinoid intoxication: a case series and review. J Emerg Med. 2013;44:360-6.
29. Gunderson EW. Synthetic cannabinoids: a new frontier of designer drugs. Ann Inter Med. 2013;159:563-4.
30. Gunderson EW, Haughey HM, Ait-Daoud N, Joshi AS, Hart CL. "Spice" and "K2" herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict. 2012;21:320-6.
31. Auwarter V, Dresen S, Weinmann W, Muller M, Putz M, Ferreiros N. 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom. 2009;44:832-7.
32. Brewer TL, Collins M. A review of clinical manifestations in adolescent and young adults after use of synthetic cannabinoids. J Spec Pediatr Nurs. 2014;19:119-26.
33. Hurst D, Loeffler G, McLay R. Psychosis associated with synthetic cannabinoid agonists: a case series. Am J Psychiatry. 2011;168:1119.
34. Muller H, Sperling W, Kohrmann M, Huttner HB, Kornhuber J, Maler JM. The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res. 2010;118:309-10.
35. Zimmermann US, Winkelmann PR, Pilhatsch M, Nees JA, Spanagel R, Schulz K. Withdrawal phenomena and dependence syndrome after the consumption of "spice gold". Dtsch Arztebl Int. 2009;106:464-7.
36. Vandrey R, Dunn KE, Fry JA, Girling ER. A survey study to characterize use of Spice products (synthetic cannabinoids). Drug Alcohol Depend. 2012;120:238-41.
37. Young AC, Schwarz E, Medina G, Obafemi A, Feng SY, Kane C. Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. Am J Emerg Med. 2012;30:1320. e5-7.
38. Hopkins CY, Gilchrist BL. A case of cannabinoid hyperemesis syndrome caused by synthetic cannabinoids. J Emerg Med. 2013;45:544-6.
39. Woo TM, Hanley JR. "How high do they look?": identification and treatment of common ingestions in adolescents. J Pediatr Health Care. 2013;27:135-44.
40. Bhanushali GK, Jain G, Fatima H, Leisch LJ, Thornley-Brown D. AKI associated with synthetic cannabinoids: a case series. Clin J Am Soc Nephrol. 2013;8:523-6.
41. Kazory A, Aiyer R. Synthetic marijuana and acute kidney injury: an unforeseen association. Clin Kidney J. 2013;6:330-3.
42. Hermanns-Clausen M, Kneisel S, Szabo B, Auwarter V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction. 2013;108:534-44.
43. Mir A, Obafemi A, Young A, Kane C. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics. 2011;128:e1622-7.
44. Fattore L, Fratta W. Beyond THC: the new generation of cannabinoid designer drugs. Front Behav Neurosci. 2011;5:60.
45. Hazekamp A, Ruhaak R, Zuurman L, van Gerven J, Verpoorte R. Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. J Pharm Sci. 2006;95:1308-17.
46. Vardakou I, Pistos C, Spiliopoulou C. Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett. 2010;197:157-62.
47. Dean BV, Stellpflug SJ, Burnett AM, Engebretsen KM. 2C or not 2C: phenethylamine designer drug review. J Med Toxicol. 2013;9:172-8.
48. Drug Enforcement Administration, U.S. Department of Justice. Schedules of controlled substances: temporary placement of three synthetic cathinones in Schedule I. Final Order. Fed Regist. 2011;76:65371.
49. Nichols DE, Frescas SP, Chemel BR, Rehder KS, Zhong D, Lewin AH. High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand. Bioorg Med Chem. 2008;16:6116-23.
50. Rose SR, Poklis JL, Poklis A. A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist designer drug. Clin Toxicol (Phila). 2013;51:174-7.
51. Lawn W, Barratt M, Williams M, Horne A, Winstock A. The NBOMe hallucinogenic drug series: patterns of use, characteristics of users and self-reported effects in a large international sample. J Psychopharmacol. 2014;28:780-8.
52. Hill SL, Doris T, Gurung S, Katebe S, Lomas A, Dunn M. Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: case series. Clin Toxicol (Phila). 2013;51:487-92.
53. Stellpflug SJ, Kealey SE, Hegarty CB, Janis GC. 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl) methyl] ethanamine (25I-NBOMe): clinical case with unique confirmatory testing. J Med Toxicol. 2014;10:45-50.
54. Weaver MF, Schnoll SH. Hallucinogens and club drugs. In: Galanter M, Kleber HD, editors. In The American Psychiatric Publishing Textbook of Substance Abuse Treatment. 4th ed. Washington, DC: American Psychiatric Press; 2008. p. 191-200.
55. Poklis JL, Devers KG, Arbefeville EF, Pearson JM, Houston E, Poklis A. Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl) methyl] ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death. Forensic Sci Int. 2014;234:e14-20.
56. Walterscheid JP, Phillips GT, Lopez AE, Gonsoulin ML, Chen H-H, Sanchez LA. Pathological findings in 2 cases of fatal 25I-NBOMe Toxicity. Am J Forensic Med Pathol. 2014;35:20-5.
57. Zamengo L, Frison G, Gregio M, Orru G, Sciarrone R. Determination of illicit drugs in seized materials: role of sampling and analysis in estimation of measurement uncertainty. Forensic Sci Int. 2011;208:108-23.
58. Lindigkeit R, Boehme A, Eiserloh I, Luebbecke M, Wiggermann M, Ernst L. Spice: a never ending story? Forensic Sci Int. 2009;191:58-63.
59. Walker D, Neighbors C, Walton T, Pierce A, Mbilinyi L, Kaysen D. Spicing up the military: use and effects of synthetic cannabis in substance abusing army personnel. Addict Behav. 2014;39:1139-44.
60. Maxwell JC. Psychoactive substances-some new, some old: a scan of the situation in the U.S. Drug Alcohol Depend. 2014;134:71-7.
61. Gahlinger PM. Club drugs: MDMA, gamma-hydroxybutyrate (GHB), Rohypnol, and ketamine. Am Fam Physician. 2004;69:2619-26.
62. Chakraborty K, Neogi R, Basu D. Club drugs: review of the 'rave' with a note of concern for the Indian scenario. Indian J Med Res. 2011;133:594-604.
63. Gunderson EW, Kirkpatrick MG, Willing LM, Holstege CP. Intranasal substituted cathinone "bath salts" psychosis potentially exacerbated by diphenhydramine. J Addict Med. 2013;7:163-8.
64. Weaver M. Substance-related disorders. In: Levenson JL, editor. In Textbook of Psychosomatic Medicine. 2nd ed. Washington, DC: American Psychiatric Press; 2010. p. 381-403.
65. Simmons J, Cookman L, Kang C, Skinner C. Three cases of "spice" exposure. Clin Toxicol (Phila). 2011;49:431-3.
66. Haddad PM, Dursun SM. Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol. 2008;23 Suppl 1:15-26.
67. Nunes EV, Levin FR. Treatment of co-occurring depression and substance dependence: using meta-analysis to guide clinical recommendations. Psychiatr Ann. 2008;38:730-8.
68. Martins SS, Copersino ML, Soderstrom CA, Smith GS, Dischinger PC, McDuff DR. Sociodemographic characteristics associated with substance use status in a trauma inpatient population. J Addict Dis. 2007;26:53-62.
69. Weaver MF, Jarvis MA, Schnoll SH. Role of the primary care physician in problems of substance abuse. Arch Intern Med. 1999;159:913-24.
70. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284:1689-95.
71. Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2007;64:830-42.
72. Maxwell JC, Spence RT. Profiles of club drug users in treatment. Subst Use Misuse. 2005;40:1409-26.
73. Harwood H, Malhotra D, Villarivera C, Liu C, Chong U, Gilani J. Cost effectiveness and cost benefit analysis of substance abuse treatment: a literature review. In Cost Effectiveness and Cost Benefit Analysis of Substance Abuse Treatment: A Literature Review. Falls Church: The Lewin Group; 2002.